PROVIDENCE, Rhode Island, April 1 (Reuters) - Investment advisors say a buildup of problems ⁠is ⁠weighing on clients, who are entering the second quarter ⁠of the year struggling with trying to predict ...

Investment advisors say a buildup of problems is weighing on clients, who are entering the second quarter of the year struggling with trying to predict the outcome of war, the direction of energy ...

Cambridge, MA (March 23, 2026) — A team of astronomers led by the Center for Astrophysics | Harvard and Smithsonian have for the first time used galactic archaeology, the study of detailed chemical ...

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Kurt Schlosser on Mar 19, 2026 at ...

Studies are showing that the inflammatory condition can impact organs across the body, not just those involved in reproduction. Many people with the most severe forms of endometriosis undergo excision ...

Jaylen Brown opens up about his relationship with Jayson Tatum. He also added that both of them are on the same page, and that’s bringing another title for the Boston Celtics. Before Jayson Tatum ...

Miniature organs grown in the lab can organize themselves into complex shapes. But they never do it the same way twice, which makes it hard to use these so-called "organoids" to study disease. Now, ...

Over the next decade, the global market for decision-making AI agents could multiply by a factor of more than 25 to a value of $215 billion. C3.ai is a player in that market, but its sales are slowing ...

Anyone who's ever grown an indeterminate tomato plant or sprawling squash vine in their garden knows that many edibles need a strong support system to maximize your harvest. But as easy as it is to ...

March 04, 2026 - Dynamic pricing sits at the focal point of regulatory crosshairs. Also called algorithmic or "surveillance pricing," this type of pricing uses customers' personal data to set ...

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. As the first med to selectively ...